Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 27, 2025 10:49 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Modus Therapeutics genomför fullt säkerställd företrädesemission om 28,3 miljoner kronor

STOCKHOLM, SVERIGE 27 juni 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Modus Therapeutics genomför en fullt säkerställd företrädesemission av units om...
June 27, 2025 10:49 ET | Source: Karolinska Development AB (publ)

Karolinska Development's portfolio company Modus Therapeutics carries out a fully secured rights issue of SEK 28.3 million

STOCKHOLM, SWEDEN June 27, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics carries out a fully secured rights issue of units of...
June 04, 2025 03:46 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag OssDsign genomför riktad nyemission om cirka 158 miljoner SEK, uppdaterar strategi och reviderar finansiella mål

STOCKHOLM, 4 juni 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget OssDsign har genomfört en riktad nyemission genom ett accelererat bookbuilding-förfarande som...
June 04, 2025 03:46 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company OssDsign raises approximately SEK 158 million, announces an updated strategy and revises financial targets

STOCKHOLM, SWEDEN, June 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has carried out a directed share issue through an accelerated...
May 26, 2025 02:50 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Umecrine Cognition återupptar patientrekrytering till klinisk fas 1b/2a-studie

STOCKHOLM, 26 maj 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition har återupptagit inkluderingen av patienter till den kliniska fas...
May 26, 2025 02:50 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company Umecrine Cognition resumes patient inclusion in its Phase 1b/2a clinical study

STOCKHOLM, SWEDEN – May 26, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has resumed the inclusion of patients to the clinical...
May 15, 2025 10:45 ET | Source: Karolinska Development AB (publ)

Karolinska Developments årsstämma 2025

STOCKHOLM, SVERIGE – 15 maj 2025. Karolinska Development AB (publ) (”Karolinska Development” eller ”Bolaget”) har den 15 maj 2025 hållit sin årsstämma. Aktieägare har före årsstämman haft möjlighet...
May 15, 2025 10:45 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s Annual General Meeting 2025

STOCKHOLM, SWEDEN – May 15, 2025. Karolinska Development AB (publ) (“Karolinska Development” or the “Company”) held the Annual General Meeting on May 15, 2025. The shareholders have had the right to...
May 13, 2025 06:45 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag OssDsign har behandlat 10 000 patienter med OssDsign Catalyst i USA

STOCKHOLM, 13 maj 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget OssDsign uppnått en ny milstolpe och behandlat 10 000 patienter med det innovativa...
May 13, 2025 06:45 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company OssDsign has treated 10,000 patients with OssDsign Catalyst in the US

STOCKHOLM, SWEDEN, May 13, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has reached a new milestone with 10,000 patients treated with the...